Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding their earlier outlook.</li><li>Adjusted earnings per share came in at $1.06, surpassing guidance by a modest margin.</li><li>The company’s Life Sciences segment grew 3% organically, driven by low single-digit growth in reagents and mid-single-digit growth in instrumentation, while the Diagnostics segment grew 4% organically, bolstered by strong double-digit growth in Reproductive Health and stable performance in Immunodiagnostics outside China.</li></ul>

Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding their earlier outlook.Adjusted earnings per share came in at $1.06, surpassing guidance by a modest margin.The company’s Life Sciences segment grew 3% organically, driven by low single-digit growth in reagents and mid-single-digit growth in instrumentation, while the Diagnostics segment grew 4% organically, bolstered by strong double-digit growth in Reproductive Health and stable performance in Immunodiagnostics outside China.

Revvity: From China Exit to SaaS Momentum—A Strategic Reset Taking Shape!

<ul><li>Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.</li><li>The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.</li><li>Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.</li></ul>

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue guidance to $772 million, exceeding Wall Street expectations.The company’s preliminary results, released ahead of its presentation at the JPMorgan Healthcare Conference, came as a surprise to a market that had seen RVTY down 9% over the past 12 months.Yet, despite the better-than-expected guidance and a solid 2026 margin outlook, investor sentiment remains cautious.

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

<ul><li>Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned with expectations despite unfavorable forex fluctuations.</li><li>The company's Signals software division proved a strong performer, with 20% organic growth, and their reproductive health segment also showed notable progress.</li><li>However, the Diagnostic segment experienced a significant decline in China due to lingering DRG impacts, though the non-China segment performed robustly, growing in the high single digits.</li></ul>

Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned with expectations despite unfavorable forex fluctuations.The company's Signals software division proved a strong performer, with 20% organic growth, and their reproductive health segment also showed notable progress.However, the Diagnostic segment experienced a significant decline in China due to lingering DRG impacts, though the non-China segment performed robustly, growing in the high single digits.

Revvity: Can It Reignite Growth With New Product Launches & Strategic Partnerships?

<ul>
<li>Revvity Inc.'s Q2 2025 results reflect steady performance amidst challenging market and regulatory conditions.</li>
<li>Organic revenue growth of 3% was achieved, aligning with the company's initial forecasts.</li>
<li>Revenue reached $720 million, bolstered by strong performances, particularly in the Life Sciences segment, which saw 4% organic growth.</li>
</ul>


Revvity Inc.'s Q2 2025 results reflect steady performance amidst challenging market and regulatory conditions.
Organic revenue growth of 3% was achieved, aligning with the company's initial forecasts.
Revenue reached $720 million, bolstered by strong performances, particularly in the Life Sciences segment, which saw 4% organic growth.


Revvity Is Balancing FX Gains, Margin Challenges, & Growth—Which Side Will Win Out?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

United States

Revvity, Inc. provides health science solutions, technologies, expertise, and services. The Company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and other areas. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Revvity (RVTY US)

Revvity: From China Exit to SaaS Momentum—A Strategic Reset Taking Shape!

Revvity reported first quarter 2026 results demonstrating 3% total company organic growth alongside adjusted operating margins of 23.6%, exceeding...

Baptista Research

Revvity Popped On Earnings Boost—Will Feb. 2 Spark The Next Big Move?

Revvity shares surged over 9% after the health-sciences company raised its 2025 earnings per share outlook above $5.00 and boosted Q4 revenue...

Baptista Research

Revvity: Can It Reignite Growth With New Product Launches & Strategic Partnerships?

Revvity's third-quarter 2025 results demonstrate a stable performance amid a challenging market landscape, with organic growth of 1% that aligned...

Baptista Research

Revvity Is Balancing FX Gains, Margin Challenges, & Growth—Which Side Will Win Out?

Revvity Inc.'s Q2 2025 results reflect steady performance amidst challenging market and regulatory conditions. Organic revenue growth of 3% was...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)